查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1356890

囊腫纖維化市場報告：至2030年的趨勢、預測與競爭分析

Cystic Fibrosis Market Report: Trends, Forecast and Competitive Analysis to 2030
出版日期: | 出版商: Lucintel | 英文 150 Pages | 商品交期: 3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

囊腫纖維化趨勢與預測

到2030年，全球囊腫纖維化市場預計將達到 109 億美元，2024年至2030年年複合成長率為 8.6%。這個市場的主要促進因素是基因組變異病例數量的增加，患者對口服療法的偏好增加以及管道患者數量的增加。全球囊腫纖維化市場的未來性充滿希望，零售藥局/藥局、線上藥局和醫院藥局市場充滿機會。

囊腫纖維化市場洞察

Lucintel預測，由於目的是改善細胞體功能，改善患者生活品質，減少肺炎和呼吸道症狀的擴大應用，囊腫纖維化跨膜傳導調節蛋白將在預測期內出現最高成長率。

預計線上藥局在預測期內將出現最高成長。

由於患有各種呼吸道疾病的患者數量不斷增加、醫療基礎設施的持續進步以及關鍵參與者的存在，預計北美在預測期內將出現最高的成長。

本報告回答了 11 個關鍵問題：

  • Q.1.細分市場中最有前途和高成長的機會為何？
  • Q.2.哪個細分市場將以更快的速度成長？理由為何？
  • Q.3.哪些地區未來會出現更快的成長？理由為何？
  • Q.4.影響市場動態的主要因素有哪些？市場的主要挑戰和商業風險是什麼？
  • Q.5.這個市場的商業風險和競爭威脅為何？
  • Q.6.這個市場有哪些新趨勢？理由為何？
  • Q.7.市場客戶需求有何改變？
  • Q.8.該市場有哪些新發展以及哪些公司處於領先地位？
  • Q.9.這個市場的主要企業有哪些？主要企業採取哪些策略配合措施來發展業務？
  • Q.10.該市場上的競爭產品有哪些？由於材料或產品替代而導致市場佔有率下降的威脅有多大？
  • Q.11.過去年度發生了哪些併購事件，對產業產生了哪些影響？

目錄

第1章 執行摘要

第2章 全球囊腫纖維化市場：市場動態

  • 簡介、背景、分類
  • 供應鏈
  • 產業促進因素與挑戰

第3章 2018-2030年市場趨勢及預測分析

  • 宏觀經濟趨勢（2018-2023）與預測（2024-2030）
  • 全球囊腫纖維化市場趨勢（2018-2023）與預測（2024-2030）
  • 按藥物類別分類的全球囊腫纖維化市場
    • 囊腫纖維化跨膜傳導調節蛋白
    • 支氣管擴張劑
    • 黏液溶解劑
    • 胰酵素補充劑
    • 其他
  • 按給藥途徑的全球囊腫纖維化市場
    • 口服
    • 胃腸外
  • 全球囊腫纖維化市場，依最終用途
    • 零售藥局和藥局
    • 網路藥房
    • 醫院藥房
    • 其他

第4章 2018-2030年市場趨勢及預測分析，依地區

  • 全球囊腫纖維化市場，依地區
  • 北美洲囊腫纖維化市場
  • 歐洲囊腫纖維化市場
  • 亞太地區囊腫纖維化市場
  • 其他區域囊腫纖維化市場

第5章 競爭分析

  • 產品系列分析
  • 營運整合
  • 波特五力分析

第6章 成長機會與策略分析

  • 成長機會分析
    • 全球囊腫纖維化市場成長機會，按藥物類別
    • 全球囊腫纖維化市場成長機會，按給藥途徑
    • 全球囊腫纖維化市場成長機會，依最終用途
    • 全球囊腫纖維化市場成長機會，依地區
  • 全球囊腫纖維化市場的新興趨勢
  • 戰略分析
    • 新產品開發
    • 全球囊腫纖維化市場容量擴張
    • 全球囊腫纖維化市場的合併、收購與合資企業
    • 認證和許可

第7章 主要企業概況

  • Gilead Sciences
  • Vertex Pharmaceuticals
  • Novartis
  • Allergan
  • AbbVie
  • Teva Pharmaceutical Industries
  • F. Hoffmann-La Roche
  • Pharmaxis
  • Mylan
  • GlaxoSmithKline
簡介目錄

Cystic Fibrosis Trends and Forecast

The future of the global cystic fibrosis market looks promising with opportunities in the retail pharmacy & drug store, online pharmacy, and hospital pharmacy markets. The global cystic fibrosis market is expected to reach an estimated $10.9 billion by 2030 with a CAGR of 8.6% from 2024 to 2030. The major drivers for this market are growing cases of genomic mutations, rising patients preference for oral treatment, and augmenting number of pipeline patients.

A more than 150-page report is developed to help in your business decisions.

Cystic Fibrosis by Segment

The study includes a forecast for the global cystic fibrosis by drug class, route of administration, end use, and region.

Cystic Fibrosis Market by Drug Class [Shipment Analysis by Value from 2018 to 2030]:

  • Cystic Fibrosis Transmembrane Conductance Regulator (CFTR)
  • Bronchodilators
  • Mucolytic
  • Pancreatic Enzyme Supplement
  • Others

Cystic Fibrosis Market by Route of Administration [Shipment Analysis by Value from 2018 to 2030]:

  • Oral
  • Parenteral

Cystic Fibrosis Market by End Use [Shipment Analysis by Value from 2018 to 2030]:

  • Retail Pharmacies & Drug Stores
  • Online Pharmacies
  • Hospital Pharmacies
  • Others

Cystic Fibrosis Market by Region [Shipment Analysis by Value from 2018 to 2030]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

List of Cystic Fibrosis Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies cystic fibrosis companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the cystic fibrosis companies profiled in this report include-

  • Gilead Sciences
  • Vertex Pharmaceuticals
  • Novartis
  • Allergan
  • Abbvie
  • Teva Pharmaceutical Industries
  • F. Hoffmann-La Roche
  • Pharmaxis
  • Mylan
  • Glaxosmithkline

Cystic Fibrosis Market Insights

Lucintel forecasts that cystic fibrosis transmembrane conductance regulator is expected to witness highest growth over the forecast period due to its expanding use to improve cellular body function, enhance patients' quality of life, and lessen lung flare-ups and respiratory symptoms.

Online pharmacy is expected to witness highest growth over the forecast period.

North America is expected to witness highest growth over the forecast period due to increasing number of people with various respiratory diseases, continous healthcare infrastructural advancement, and presence of key players in the region.

Features of the Global Cystic Fibrosis Market

Market Size Estimates: Cystic fibrosis market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Cystic fibrosis market size by various segments, such as by route of administration, end use, and region. in terms of value ($B).

Regional Analysis: Cystic fibrosis market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different route of administrations, end uses, and region.s for the cystic fibrosis market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the cystic fibrosis market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q.1. What is the cystic fibrosis market size?

Answer: The global cystic fibrosis market is expected to reach an estimated $10.9 billion by 2030.

Q.2. What is the growth forecast for cystic fibrosis market?

Answer: The global cystic fibrosis market is expected to grow with a CAGR of 8.6% from 2024 to 2030.

Q.3. What are the major drivers influencing the growth of the cystic fibrosis market?

Answer: The major drivers for this market are growing cases of genomic mutations, rising patients preference for oral treatment, and augmenting number of pipeline patients.

Q.4. What are the major segments for cystic fibrosis market?

Answer: The future of the cystic fibrosis market looks promising with opportunities in the retail pharmacy & drug store, online pharmacy, and hospital pharmacy markets.

Q.5. Who are the key cystic fibrosis market companies?

Answer: Some of the key cystic fibrosis companies are as follows:

  • Gilead Sciences
  • Vertex Pharmaceuticals
  • Novartis
  • Allergan
  • AbbVie
  • Teva Pharmaceutical Industries
  • F. Hoffmann-La Roche
  • Pharmaxis
  • Mylan
  • GlaxoSmithKline

Q.6. Which cystic fibrosis market segment will be the largest in future?

Answer: Lucintel forecasts that cystic fibrosis transmembrane conductance regulator is expected to witness highest growth over the forecast period due to its expanding use to improve cellular body function, enhance patients' quality of life, and lessen lung flare-ups and respiratory symptoms.

Q.7. In cystic fibrosis market, which region is expected to be the largest in next 5 years?

Answer: North America is expected to witness highest growth over the forecast period due to increasing number of people with various respiratory diseases, continous healthcare infrastructural advancement, and presence of key players in the region.

Q.8. Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the cystic fibrosis market by drug class (cystic fibrosis transmembrane conductance regulator (CFTR), bronchodilators, mucolytic, pancreatic enzyme supplement, and others), route of administration (oral and parenteral), end use (retail pharmacies & drug stores, online pharmacies, hospital pharmacies, and others), and region. (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Cystic Fibrosis Market : Market Dynamics

  • 2.1: Introduction, Background, and Classifications
  • 2.2: Supply Chain
  • 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

  • 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
  • 3.2. Global Cystic Fibrosis Market Trends (2018-2023) and Forecast (2024-2030)
  • 3.3: Global Cystic Fibrosis Market by Drug Class
    • 3.3.1: Cystic Fibrosis Transmembrane Conductance Regulator
    • 3.3.2: Bronchodilators
    • 3.3.3: Mucolytic
    • 3.3.4: Pancreatic Enzyme Supplement
    • 3.3.5: Others
  • 3.4: Global Cystic Fibrosis Market by Route of Administration
    • 3.4.1: Oral
    • 3.4.2: Parenteral
  • 3.5: Global Cystic Fibrosis Market by End Use
    • 3.5.1: Retail Pharmacies & Drug Stores
    • 3.5.2: Online Pharmacies
    • 3.5.3: Hospital Pharmacies
    • 3.5.4: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

  • 4.1: Global Cystic Fibrosis Market by Region
  • 4.2: North American Cystic Fibrosis Market
    • 4.2.2: North American Cystic Fibrosis Market by End Use: Retail Pharmacies & Drug Stores, Online Pharmacies, Hospital Pharmacies, and Others
  • 4.3: European Cystic Fibrosis Market
    • 4.3.1: European Cystic Fibrosis Market by Drug Class: Cystic Fibrosis Transmembrane Conductance Regulator, Bronchodilators, Mucolytic, Pancreatic Enzyme Supplement, and Others
    • 4.3.2: European Cystic Fibrosis Market by End Use: Retail Pharmacies & Drug Stores, Online Pharmacies, Hospital Pharmacies, and Others
  • 4.4: APAC Cystic Fibrosis Market
    • 4.4.1: APAC Cystic Fibrosis Market by Drug Class: Cystic Fibrosis Transmembrane Conductance Regulator, Bronchodilators, Mucolytic, Pancreatic Enzyme Supplement, and Others
    • 4.4.2: APAC Cystic Fibrosis Market by End Use: Retail Pharmacies & Drug Stores, Online Pharmacies, Hospital Pharmacies, and Others
  • 4.5: ROW Cystic Fibrosis Market
    • 4.5.1: ROW Cystic Fibrosis Market by Drug Class: Cystic Fibrosis Transmembrane Conductance Regulator, Bronchodilators, Mucolytic, Pancreatic Enzyme Supplement, and Others
    • 4.5.2: ROW Cystic Fibrosis Market by End Use: Retail Pharmacies & Drug Stores, Online Pharmacies, Hospital Pharmacies, and Others

5. Competitor Analysis

  • 5.1: Product Portfolio Analysis
  • 5.2: Operational Integration
  • 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

  • 6.1: Growth Opportunity Analysis
    • 6.1.1: Growth Opportunities for the Global Cystic Fibrosis Market by Drug Class
    • 6.1.2: Growth Opportunities for the Global Cystic Fibrosis Market by Route of Administration
    • 6.1.3: Growth Opportunities for the Global Cystic Fibrosis Market by End Use
    • 6.1.4: Growth Opportunities for the Global Cystic Fibrosis Market by Region
  • 6.2: Emerging Trends in the Global Cystic Fibrosis Market
  • 6.3: Strategic Analysis
    • 6.3.1: New Product Development
    • 6.3.2: Capacity Expansion of the Global Cystic Fibrosis Market
    • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Cystic Fibrosis Market
    • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

  • 7.1: Gilead Sciences
  • 7.2: Vertex Pharmaceuticals
  • 7.3: Novartis
  • 7.4: Allergan
  • 7.5: AbbVie
  • 7.6: Teva Pharmaceutical Industries
  • 7.7: F. Hoffmann-La Roche
  • 7.8: Pharmaxis
  • 7.9: Mylan
  • 7.10: GlaxoSmithKline